EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

H Mocikova, L Gaherova, T Jancarkova, A Suri, A Janikova, K Steinerova, D Belada, R Pytlik, J Duras, M Trnkova, P Blahovcova, T Kozak und 1 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70193 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von H Mocikova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Methotrexate, Central Nervous System Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, the Cooperatio Program, research area "Oncology and Haematology".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk CNS International Prognostic Index (CNS‐IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m 2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). Patients with low‐risk CNS‐IPI did not receive MTX prophylaxis (arm C). The primary objective was to compare the cumulative incidence of CNS relapse between arms A and B. Secondary objectives included evaluation of overall response rate (ORR), complete remission rate (CRR), progression‐free survival (PFS), overall survival (OS), and treatment‐related safety across all arms. Between 7/2015 and 5/2024, a total of 100 patients were enrolled: 30 in arm A, 31 in arm B, and 39 in arm C. ORR did not differ among arms ( p = 0.20). During a median follow‐up of 54.9 months, CNS relapses were observed in three patients who had received MTX prophylaxis‐one in arm A and two in arm B. The 5‐year cumulative incidence of CNS relapse was 0% in arm A and 8.7% in arm B ( p = 0.72). However, due to the small sample size, the primary endpoint results are inconclusive. Median PFS was comparable between arms A and B (HR 0.66, p = 0.20). MTX i.v. was associated with a significantly higher grade ≥ 3 neutropenia ( p = 0.0003) and infection ( p = 0.0063). The higher infection rate contributed to a worse 5‐year OS in arm A versus B (47.2% vs. 72.4%, HR 0.46, p = 0.04). Conclusion: our trial faced limitations due to a low number of randomized participants, making the interpretation of results challenging. A larger, international randomized trial is necessary to determine the benefit of CNS prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsMethotrexateCentral Nervous System NeoplasmsHumansFemaleMaleMiddle AgedDoxorubicinCyclophosphamideProspective StudiesVincristineAgedAdultPrednisoneRituximabEtoposide

Stichwörter der Autor:innen

CNS prophylaxisCNS relapseCNS‐IPIdiffuse large B‐cell lymphomamethotrexate

Substanzen

MethotrexateDoxorubicinCyclophosphamideVincristinePrednisoneRituximabEtoposideR-CHOP protocol

Autor:innen und Institutionen

  • Department of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Clinical Hematology, University Hospital, Pilsen, Czech Republic.
  • Department of Internal Medicine- Hematology, University Hospital and Faculty of Medicine, Pilsen, Czech Republic.
  • Cell Therapy Department, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
  • Ist Department of Medicine, General University Hospital, Ist Faculty of Medicine, Charles University, Prague, Czech Republic.

ORCID-Profile: M Trneny

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky
  • the Cooperatio Program, research area "Oncology and Haematology"

Zitieren

APA

Mocikova, H., Gaherova, L., Jancarkova, T., Suri, A., Janikova, A., Steinerova, K., Belada, D., Pytlik, R., Duras, J., Trnkova, M., Blahovcova, P., Kozak, T., & Trneny, M. (2026). The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial. Hematological Oncology. https://doi.org/10.1002/hon.70193

Vancouver

Mocikova H, Gaherova L, Jancarkova T, Suri A, Janikova A, Steinerova K, et al. The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial. Hematological Oncology. 2026. doi:10.1002/hon.70193

BibTeX
@article{Mocikova2026,
  author = {Mocikova, H and Gaherova, L and Jancarkova, T and Suri, A and Janikova, A and Steinerova, K and Belada, D and Pytlik, R and Duras, J and Trnkova, M and Blahovcova, P and Kozak, T and Trneny, M},
  title = {The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70193}
}
Kostenlos starten →